Implants and methods for treating inflammation-mediated conditions of the eye

Abstract

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.

1 . A bioerodible implant for treating an inflammation-mediated condition of the eye, the implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, the implant structured to be placed in the vitreous of the eye and deliver the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 μg/ml dexamethasone within about 6 hours and maintain a concentration equivalent to at least about 0.01 μg/ml dexamethasone for at least about three weeks, wherein the steroidal anti-inflammatory agent is fluocinolone acetonide. 
     
     
         2 . A bioerodible implant for treating an inflammation-mediated condition of the eye, the implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, the implant structured to be placed in the vitreous of the eye and deliver the agent to the vitreous in an amount sufficient to reach an in vivo concentration equivalent to at least 0.05 μg/mL dexamethasone within about 48 hours and to maintain an in vivo concentration equivalent to at least about 0.03 μg/mL dexamethasone for at least about three weeks, wherein the total weight of the implant is about 250-5000 μg. 
     
     
         3 . The implant of  claim 2 , wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer. 
     
     
         4 . The implant of  claim 2 , wherein the steroidal anti-inflammatory agent comprises about 10 to 90% by weight of the implant. 
     
     
         5 . The implant of  claim 2 , wherein the steroidal anti-inflammatory agent comprises about 50 to about 80% by weight of the implant.